189 related articles for article (PubMed ID: 15559242)
1. [The best approach to treat prolactinoma].
Zárate A; Saucedo R; Basurto L
Gac Med Mex; 2004; 140(5):567-9. PubMed ID: 15559242
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of prolactinoma with a new dopamine agonist].
Svoboda T; Luger A; Knosp E; Geyer G
Dtsch Med Wochenschr; 1991 Aug; 116(33):1224-7. PubMed ID: 1678695
[TBL] [Abstract][Full Text] [Related]
4. Medical therapy of prolactinomas.
Jaquet P
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():31-3. PubMed ID: 8103957
[TBL] [Abstract][Full Text] [Related]
5. [Macroprolactinoma resistant to bromocriptine].
López-Espinosa E; Ayala AR; Grimaldo J; Kunhardt J; Villanueva C
Arch Invest Med (Mex); 1989; 20(1):1-8. PubMed ID: 2669670
[TBL] [Abstract][Full Text] [Related]
6. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic evaluation of hyperprolactinemia.
Biller BM
J Reprod Med; 1999 Dec; 44(12 Suppl):1095-9. PubMed ID: 10649817
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
van der Lely AJ; Brownell J; Lamberts SW
J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
[TBL] [Abstract][Full Text] [Related]
9. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
Hong JW; Lee MK; Kim SH; Lee EJ
Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonists and pituitary tumor shrinkage.
Bevan JS; Webster J; Burke CW; Scanlon MF
Endocr Rev; 1992 May; 13(2):220-40. PubMed ID: 1352243
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
12. The use of surgery for the treatment of prolactinomas.
van't Verlaat JW
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
[TBL] [Abstract][Full Text] [Related]
13. When to discontinue treatment of prolactinoma?
Wass JA
Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):298-9. PubMed ID: 16932302
[No Abstract] [Full Text] [Related]
14. [Hyperprolactinemia].
Müller OA; von Werder K
Z Arztl Fortbild (Jena); 1991 Feb; 85(3-4):125-30. PubMed ID: 1676201
[No Abstract] [Full Text] [Related]
15. [Prolactinoma is more frequent among men than among women. A dopamine agonist is effective in the treatment].
Hulting AL; Muhr C; Lundberg PO; Werner S
Lakartidningen; 1990 Dec; 87(50):4335-7. PubMed ID: 1980709
[No Abstract] [Full Text] [Related]
16. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.
Vilar L; Naves LA; Freitas MC; Lima M; Canadas V; Albuquerque JL; Lyra R; Azevedo MF; Casulari LA
Minerva Endocrinol; 2007 Jun; 32(2):79-86. PubMed ID: 17557033
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
[TBL] [Abstract][Full Text] [Related]
18. [Macroprolactinoma reduction and pregnancy induction with bromocriptine].
Grimaldo J; López Espinoza E; Villanueva C; Verulo Reyes TB; Ayala AR
Ginecol Obstet Mex; 1988 Aug; 56():213-7. PubMed ID: 3154241
[No Abstract] [Full Text] [Related]
19. Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
Bronstein MD
Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):130-1. PubMed ID: 16932269
[No Abstract] [Full Text] [Related]
20. [Therapy of micro- and macroprolactinoma. Must dopamine agonists be given lifelong?].
von Werder K
Dtsch Med Wochenschr; 1991 Jan; 116(1):25-7. PubMed ID: 1670764
[No Abstract] [Full Text] [Related]
[Next] [New Search]